Skip to main content

Advertisement

SpringerLink
Log in

Recurrence pattern in glioblastoma multiforme patients treated with anti-angiogenic chemotherapy

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

Glioblastoma multiforme is the prototype of an angiogenic tumour. Under experimental conditions, anti-angiogenic therapy strategies lead to an increased invasion. Here we report on the pattern of tumour recurrence in glioblastoma patients treated with an anti-angiogenic chemotherapy.

Patients and methods

A total of 32 patients with glioblastoma multiforme and a residual tumour mass after operation were treated with a continuous low-dose chemotherapy with temozolomide and a COX-II inhibitor, a presumably anti-angiogenic therapy.

Results

While anti-tumour activity of this therapy regimen was excellent with a mean overall time to progression of 10.4 (±0.9) months and a mean overall survival of 17.8 (±1.5) months, an unusually high rate of distant recurrences was observed (62.5%).

Conclusion

Patients treated with an anti-angiogenic chemotherapy experience distant recurrences at a higher rate than reported for conventional therapies. This may reflect an anti-angiogenic therapy-induced activation of glioma invasion confirming similar recently published experimental results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  • Bao S, Wu Q, Sathornsumetee S et al (2006) Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 66:7843–7848

    Article  PubMed  CAS  Google Scholar 

  • Bello L, Carrabba G, Giussani C et al (2001) Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res 61:7501–7506

    PubMed  CAS  Google Scholar 

  • Brockmann MA, Papadimitriou A, Brandt M et al (2003a) Inhibition of intracerebral glioblastoma growth by local treatment with the scatter factor/hepatocyte growth factor-antagonist NK4. Clin Cancer Res 9:4578–4585

    PubMed  CAS  Google Scholar 

  • Brockmann MA, Ulbricht U, Gruner K et al (2003b) Glioblastoma and cerebral microvascular endothelial cell migration in response to tumor-associated growth factors. Neurosurgery 52:1391–1399 (discussion 1399)

    Article  PubMed  Google Scholar 

  • Brockmann MA, Giese A, Mueller K et al (2007) Preoperative thrombocytosis predicts poor survival in patients with glioblastoma efficacy of different regimens of adjuvant radiochemotherapy for treatment of glioblastoma. Neuro Oncol 9:335–342

    Article  PubMed  Google Scholar 

  • Browder T, Butterfield CE, Kraling BM et al (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878–1886

    PubMed  CAS  Google Scholar 

  • Burger PC, Dubois PJ, Schold SC Jr et al (1983) Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. J Neurosurg 58:159–169

    Article  PubMed  CAS  Google Scholar 

  • Chang EL, Akyurek S, Avalos T et al (2007) Evaluation of peritumoral edema in the delineation of radiotherapy clinical target volumes for glioblastoma. Int J Radiat Oncol Biol Phys 68:144–150

    PubMed  Google Scholar 

  • Chi A, Norden AD, Wen PY (2007) Inhibition of angiogenesis and invasion in malignant gliomas. Expert Rev Anticancer Ther 7:1537–1560

    Article  PubMed  CAS  Google Scholar 

  • Coras R, Holsken A, Seufert S et al (2007) The peroxisome proliferator-activated receptor-gamma agonist troglitazone inhibits transforming growth factor-beta-mediated glioma cell migration and brain invasion. Mol Cancer Ther 6:1745–1754

    Article  PubMed  CAS  Google Scholar 

  • Eberhard A, Kahlert S, Goede V et al (2000) Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 60:1388–1393

    PubMed  CAS  Google Scholar 

  • Folkins C, Man S, Xu P et al (2007) Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res 67:3560–3564

    Article  PubMed  CAS  Google Scholar 

  • Gately S, Kerbel R (2001) Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer J 7:427–436

    PubMed  CAS  Google Scholar 

  • Ghiringhelli F, Menard C, Puig PE et al (2007) Metronomic cyclophosphamide regimen selectively depletes CD4 + CD25 + regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56:641–648

    Article  PubMed  CAS  Google Scholar 

  • Giese A, Kucinski T, Knopp U et al (2004) Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma. J Neurooncol 66:351–360

    Article  PubMed  Google Scholar 

  • Grobholz R, Bohrer MH, Siegsmund M et al (2000) Correlation between neovascularisation and neuroendocrine differentiation in prostatic carcinoma. Pathol Res Pract 196:277–284

    PubMed  CAS  Google Scholar 

  • Hanahan D, Bergers G, Bergsland E (2000) Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105:1045–1047

    Article  PubMed  CAS  Google Scholar 

  • Hochberg FH, Pruitt A (1980) Assumptions in the radiotherapy of glioblastoma. Neurology 30:907–911

    PubMed  CAS  Google Scholar 

  • Holash J, Maisonpierre PC, Compton D et al (1999) Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284:1994–1998

    Article  PubMed  CAS  Google Scholar 

  • Juni P, Nartey L, Reichenbach S et al (2004) Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 364:2021–2029

    Article  PubMed  CAS  Google Scholar 

  • Kakeji Y, Teicher BA (1997) Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest New Drugs 15:39–48

    Article  PubMed  CAS  Google Scholar 

  • Kang MK, Kang SK (2007) Tumorigenesis of chemotherapeutic drug-resistant cancer stem-like cells in brain glioma. Stem Cells Dev 16:837–847

    Article  PubMed  CAS  Google Scholar 

  • Kelly PJ, Daumas-Duport C, Kispert DB et al (1987) Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg 66:865–874

    Article  PubMed  CAS  Google Scholar 

  • Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4:423–436

    Article  PubMed  CAS  Google Scholar 

  • Klement G, Baruchel S, Rak J et al (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105:R15–R24

    Article  PubMed  CAS  Google Scholar 

  • Klement G, Huang P, Mayer B et al (2002) Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res 8:221–232

    PubMed  CAS  Google Scholar 

  • Kunkel P, Ulbricht U, Bohlen P et al (2001) Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 61:6624–6628

    PubMed  CAS  Google Scholar 

  • Lamszus K, Brockmann MA, Eckerich C et al (2005) Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin. Clin Cancer Res 11:4934–4940

    Article  PubMed  CAS  Google Scholar 

  • Maity A, Pore N, Lee J et al (2000) Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3′-kinase and distinct from that induced by hypoxia. Cancer Res 60:5879–5886

    PubMed  CAS  Google Scholar 

  • Norden AD, Young GS, Setayesh K et al (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70:779–787

    Article  PubMed  CAS  Google Scholar 

  • Oppitz U, Maessen D, Zunterer H et al (1999) 3D-recurrence-patterns of glioblastomas after CT-planned postoperative irradiation. Radiother Oncol 53:53–57

    Article  PubMed  CAS  Google Scholar 

  • Pennacchietti S, Michieli P, Galluzzo M et al (2003) Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3:347–361

    Article  PubMed  Google Scholar 

  • Reardon DA, Rich JN, Friedman HS et al (2006) Recent advances in the treatment of malignant astrocytoma. J Clin Oncol 24:1253–1265

    Article  PubMed  CAS  Google Scholar 

  • Rijken PF, Bernsen HJ, Peters JP et al (2000) Spatial relationship between hypoxia and the (perfused) vascular network in a human glioma xenograft: a quantitative multi-parameter analysis. Int J Radiat Oncol Biol Phys 48:571–582

    PubMed  CAS  Google Scholar 

  • Scheda A, Finjap JK, Tuettenberg J et al (2007) Efficacy of different regimens of adjuvant radiochemotherapy for treatment of glioblastoma. Tumori 93:31–36

    PubMed  CAS  Google Scholar 

  • Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996

    Article  PubMed  CAS  Google Scholar 

  • Teicher BA, Sotomayor EA, Huang ZD (1992) Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 52:6702–6704

    PubMed  CAS  Google Scholar 

  • Tuettenberg J, Grobholz R, Korn T et al (2005) Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme. J Cancer Res Clin Oncol 131:31–40

    Article  PubMed  CAS  Google Scholar 

  • Tuettenberg J, Friedel C, Vajkoczy P (2006) Angiogenesis in malignant glioma—a target for antitumor therapy? Crit Rev Oncol Hematol 59:181–193

    Article  PubMed  CAS  Google Scholar 

  • Vajkoczy P, Knyazev P, Kunkel A et al (2006) Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. Proc Natl Acad Sci USA 103:5799–5804

    Article  PubMed  CAS  Google Scholar 

  • Wick W, Platten M, Weller M (2001) Glioma cell invasion: regulation of metalloproteinase activity by TGF-beta. J Neurooncol 53:177–185

    Article  PubMed  CAS  Google Scholar 

  • Wick W, Naumann U, Weller M (2006) Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma. Curr Pharm Des 12:341–349

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest statement

We declare that we have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Universitätsmedizin Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany

    Jochen Tuettenberg & Marcel Seiz

  2. Department of Radiation Oncology, Universitätsmedizin Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany

    Frank Lohr & Frederik Wenz

  3. Department of Neuroradiology, Universitätsmedizin Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany

    Marc A. Brockmann

  4. Institute of Pathology, Saarland University, 66421, Homburg, Germany

    Rainer Grobholz

  5. Department of Neurosurgery, Charité, Universitätsmedizin Berlin, Berlin, Germany

    Peter Vajkoczy

Authors
  1. Jochen Tuettenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rainer Grobholz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marcel Seiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marc A. Brockmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Frank Lohr
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Frederik Wenz
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Peter Vajkoczy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jochen Tuettenberg.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tuettenberg, J., Grobholz, R., Seiz, M. et al. Recurrence pattern in glioblastoma multiforme patients treated with anti-angiogenic chemotherapy. J Cancer Res Clin Oncol 135, 1239–1244 (2009). https://doi.org/10.1007/s00432-009-0565-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-009-0565-9

Keywords

Search

Navigation